
FDA Grants Breakthrough Therapy Designation to Pemafibrate for Primary Biliary Cholangitis
As reported on PR Newswire, the US Food and Drug Administration has granted Breakthrough Therapy designation to Kowa’s investigational therapy K-808 (pemafibrate) for primary biliary





















